Sign In
Buy RDHL
$0.791
-0.0390 (-4.70%)
At Close: Jun 16, 2026
RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021
07:00am, Thursday, 20'th May 2021
TEL AVIV, Israel and RALEIGH, N.C., May 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
Could These 2 Exciting COVID Stocks be 10-Baggers?
06:15am, Sunday, 11'th Apr 2021
They're approaching the treatment-race finish line.
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
07:00am, Friday, 09'th Apr 2021
TEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill: More To Come
05:40am, Monday, 29'th Mar 2021
The pandemic has cut into RedHill's growing potential.
RedHill Biopharma announces resolution to patent litigation in the US in response to a generic version of Movantik
05:30am, Friday, 26'th Mar 2021
RedHill Biopharma Ltd. (NASDAQ:RDHL) has announced a resolution to patent litigation in the US in response to a generic version of Movantik (naloxegol) which the company acquired the global rights
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals
09:15am, Thursday, 25'th Mar 2021
TEL AVIV, Israel and RALEIGH, N.C., March 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (NASDAQ:RDHL) announced that it has acted on a request to provide its opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suf
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
07:00am, Monday, 22'nd Mar 2021
TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2020 Results - Earnings Call Transcript
01:41pm, Thursday, 18'th Mar 2021
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2020 Results - Earnings Call Transcript
RedHill Biopharma delivers revenue growth, commercial expansion and pipeline progress in FY2020 results as focused efforts pay off
12:18pm, Thursday, 18'th Mar 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) has reported FY2020 net revenue of approximately $64 million and gross profit of $27.5 million thanks to the commercialization of its Movantik and Talicia gastroin
Recap: Redhill Biopharma Q4 Earnings
08:18am, Thursday, 18'th Mar 2021
Shares of Redhill Biopharma (NASDAQ:RDHL) rose 0.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% year over year to ($0.07), which
RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
07:00am, Thursday, 18'th Mar 2021
TEL AVIV, Israel and RALEIGH, N.C., March 18, 2021 /PRNewswire/ -- Financials: Full year 2020 net revenues of approximately $64 million, with gross profit of approximately $27.5 million Solid cash bal
Earnings Preview for Redhill Biopharma
10:38am, Wednesday, 17'th Mar 2021
Redhill Biopharma (NASDAQ:RDHL) announces its next round of earnings this Thursday, March 18. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.
RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021
07:00am, Thursday, 11'th Mar 2021
TEL AVIV, Israel and RALEIGH, NC, March 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it wil
RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares
12:10pm, Thursday, 04'th Mar 2021
TEL AVIV, Israel and RALEIGH, N.C., March 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing
